| [1] |
. J Hepatol，2019，70（3）：531-544.
|
| [2] |
Guo YT，Chen J，Liu N，et al. Association of circulating TXNIP levels with fatty liver in newly diagnosed type 2 diabetes mellitus［J］. Diabetes Metab Syndr Obes，2022，15：225-233.
|
| [3] |
Sodum N，Kumar G，Bojja SL，et al. Epigenetics in NAFLD/NASH：targets and therapy［J］. Pharmacol Res，2021，167：105484.
|
| [4] |
Rives C，Fougerat A，Ellero-Simatos S，et al. Oxidative stress in NAFLD：role of nutrients and food contaminants［J］. Biomolecules，2020，10（12）：1702.
|
| [5] |
Safari Z，Gérard P. The links between the gut microbiome and non-alcoholic fatty liver disease （NAFLD）［J］. Cell Mol Life Sci，2019，76（8）：1541-1558.
|
| [6] |
Ahrari A，Najafzadehvarzi H，Taravati A，et al. The inhibitory effect of PLGA-encapsulated berberine on hepatotoxicity and α-smooth muscle actin （α-SMA） gene expression［J］. Life Sci，2021，284：119884.
|
| [7] |
Juanola O，Martínez-López S，Francés R，et al. Non-alcoholic fatty liver disease：metabolic，genetic，epigenetic and environmental risk factors［J］. Int J Environ Res Public Health，2021，18（10）：5227.
|
| [8] |
Prikhodko VA，Bezborodkina NN，Okovityi SV. Pharmacotherapy for non-alcoholic fatty liver disease：emerging targets and drug candidates［J］. Biomedicines，2022，10（2）：274.
|
| [9] |
Dufour JF，Caussy C，Loomba R. Combination therapy for non-alcoholic steatohepatitis：rationale，opportunities and challenges［J］. Gut，2020，69（10）：1877-1884.
|
| [10] |
B?ttger R，Pauli G，Chao PH，et al. Lipid-based nanoparticle technologies for liver targeting［J］. Adv Drug Deliv Rev，2020，154/155：79-101.
|
| [11] |
Peng W，Cheng SM，Bao ZH，et al. Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis［J］. Biomed Pharmacother，2021，137：111342.
|
| [12] |
Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis［J］. Expert Opin Investig Drugs，2018，27（3）：301-311.
|
| [13] |
Radun R，Trauner M. Role of FXR in bile acid and metabolic homeostasis in NASH：pathogenetic concepts and therapeutic opportunities［J］. Semin Liver Dis，2021，41（4）：461-475.
|
| [14] |
Kumar V，Xin XF，Ma JY，et al. Therapeutic targets，novel drugs，and delivery systems for diabetes associated NAFLD and liver fibrosis［J］. Adv Drug Deliv Rev，2021，176：113888.
|
| [15] |
Ratziu V，Sanyal A，Harrison SA，et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis：final analysis of the phase 2b CENTAUR study［J］. Hepatology，2020，72（3）：892-905.
|
| [16] |
Pedrosa M，Seyedkazemi S，Francque S，et al. A randomized，double-blind，multicenter，phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis：study design of the TANDEM trial［J］. Contemp Clin Trials，2020，88：105889.
|
| [17] |
Griggs LA，Hassan NT，Malik RS，et al. Fibronectin fibrils regulate TGF-β1-induced epithelial-mesenchymal transition［J］. Matrix Biol，2017，60/61：157-175.
|
| [18] |
Kumar V，Dong YX，Kumar V，et al. The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis［J］. Theranostics，2019，9（25）：7537-7555.
|
| [19] |
Kumar V，Mundra V，Mahato RI. Nanomedicines of hedgehog inhibitor and PPAR-γ agonist for treating liver fibrosis［J］. Pharm Res，2014，31（5）：1158-1169.
|
| [20] |
Romualdo GR，da Silva TC，de Albuquerque Landi MF，et al. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease［J］. Environ Toxicol，2021，36（2）：168-176.
|
| [21] |
Ma R，Chen J，Liang YL，et al. Sorafenib：a potential therapeutic drug for hepatic fibrosis and its outcomes［J］. Biomed Pharmacother，2017，88：459-468.
|
| [22] |
Chen Y，Liu YC，Sung YC，et al. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors［J］. Sci Rep，2017，7：44123.
|
| [23] |
Sung YC，Liu YC，Chao PH，et al. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development［J］. Theranostics，2018，8（4）：894-905.
|
| [24] |
Shafie F，Nabavizadeh F，Shafie Ardestani M，et al. Sorafenib-loaded PAMAM dendrimer attenuates liver fibrosis and its complications in bile-duct-ligated rats［J］. Can J Physiol Pharmacol，2019，97（8）：691-698.
|
| [25] |
Keating GM. Sorafenib：a review in hepatocellular carcinoma［J］. Target Oncol，2017，12（2）：243-253.
|
| [26] |
Qin LF，Qin JM，Zhen XM，et al. Curcumin protects against hepatic stellate cells activation and migration by inhibiting the CXCL12/CXCR4 biological axis in liver fibrosis：a study in vitro and in vivo［J］. Biomed Pharmacother，2018，101：599-607.
|
| [27] |
Lung YM，Man FY，Christian S，et al. ARO-HSD，an investigational RNAi therapeutic，demonstrates reduction in ALT and hepatic HSD17B13 mRNA and protein in patients with NASH or suspected NASH［R］. AASLD，2021. https：//www.natap.org/2021/AASLD/AASLD_99.htm.
|
| [28] |
Cui H，Zhu XY，Li SY，et al. Liver-targeted delivery of oligonucleotides with N-acetylgalactosamine conjugation［J］. ACS Omega，2021，6（25）：16259-16265.
|
| [29] |
Ji D，Wang QH，Zhao Q，et al. Co-delivery of miR-29b and germacrone based on cyclic RGD-modified nanoparticles for liver fibrosis therapy［J］. J Nanobiotechnology，2020，18（1）：86.
|
| [30] |
Yu FJ，Chen BC，Dong PH，et al. HOTAIR epigenetically modulates PTEN expression via microRNA-29b：a novel mechanism in regulation of liver fibrosis［J］. Mol Ther，2017，25（1）：205-217.
|
| [31] |
Zeng CX，Wang YL，Xie C，et al. Identification of a novel TGF-β-miR-122-fibronectin 1/serum response factor signaling cascade and its implication in hepatic fibrogenesis［J］. Oncotarget，2015，6（14）：12224-12233.
|
| [32] |
Li J，Ghazwani M，Zhang YF，et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression［J］. J Hepatol，2013，58（3）：522-528.
|
| [33] |
Wu J，Huang JS，Kuang SC，et al. Synergistic microRNA therapy in liver fibrotic rat using MRI-visible nanocarrier targeting hepatic stellate cells［J］. Adv Sci （Weinh），2019，6（5）：1801809.
|
| [34] |
Zhao Z，Li YK，Jain A，et al. Development of a peptide-modified siRNA nano complex for hepatic stellate cells［J］. Nanomedicine，2018，14（1）：51-61.
|
| [35] |
Qiao JB，Fan QQ，Zhang CL，et al. Hyperbranched lipoid-based lipid nanoparticles for bidirectional regulation of collagen accumulation in liver fibrosis［J］. J Control Release，2020，321：629-640.
|
| [36] |
Boakye CHA，Patel K，Doddapaneni R，et al. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment［J］. J Control Release，2017，246：120-132.
|
| [37] |
Gong CN，Hu CL，Gu FF，et al. Co-delivery of autophagy inhibitor ATG7 siRNA and docetaxel for breast cancer treatment［J］. J Control Release，2017，266：272-286.
|
| [38] |
Zhang BF，Xing L，Cui PF，et al. Mitochondria apoptosis pathway synergistically activated by hierarchical targeted nanoparticles co-delivering siRNA and lonidamine［J］. Biomaterials，2015，61：178-189.
|
| [39] |
Shrestha B，Wang LJ，Brey EM，et al. Smart nanoparticles for chemo-based combinational therapy［J］. Pharmaceutics，2021，13（6）：853.
|
| [40] |
Salvoza N，Giraudi PJ，Tiribelli C，et al. Natural compounds for counteracting nonalcoholic fatty liver disease （NAFLD）：advantages and limitations of the suggested candidates［J］. Int J Mol Sci，2022，23（5）：2764.
|
| [41] |
Jia JD，Bauer M，Cho JJ，et al. Antifibrotic effect of silymarin in rat secondary biliary fibrosis is mediated by downregulation of procollagen α1（I） and TIMP-1［J］. J Hepatol，2001，35（3）：392-398.
|
| [42] |
Song IS，Nam SJ，Jeon JH，et al. Enhanced bioavailability and efficacy of silymarin solid dispersion in rats with acetaminophen-induced hepatotoxicity［J］. Pharmaceutics，2021，13（5）：628.
|
| [43] |
Qiao JB，Fan QQ，Xing L，et al. Vitamin A-decorated biocompatible micelles for chemogene therapy of liver fibrosis［J］. J Control Release，2018，283：113-125.
|
| [44] |
Jung Y，Brown KD，Witek RP，et al. Accumulation of hedgehog-responsive progenitors parallels alcoholic liver disease severity in mice and humans［J］. Gastroenterology，2008，134（5）：1532-1543.
|
| [45] |
Kumar V，Mondal G，Dutta R，et al. Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis［J］. Biomaterials，2016，76：144-156.
|
| [46] |
Han J，He YP，Zhao H，et al. Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway［J］. J Cell Biochem，2019，120（9）：14735-14744.
|
| [47] |
Hong F，Tuyama A，Lee TF，et al. Hepatic stellate cells express functional CXCR4：role in stromal cell-derived factor-1alpha-mediated stellate cell activation［J］. Hepatology，2009，49（6）：2055-2067.
|
| [48] |
Liu CH，Chan KM，Chiang T，et al. Dual-functional nanoparticles targeting CXCR4 and delivering antiangiogenic siRNA ameliorate liver fibrosis［J］. Mol Pharm，2016，13（7）：2253-2262.
|
下载:
